活動性体軸型脊椎炎関節炎患者におけるビメキズマブ: フェーズ 3 BE MOBILE 1 と BE MOBILE 2 試験から52週の有効性と安全性
Ann Rheum Dis. 2023;83(2):199–213 doi 10.1136/ard-2023-224803
Baraliakos, et al. present data from two Phase 3 studies, BE MOBILE 1 and BE MOBILE 2, that investigated the clinical efficacy and safety of bimekizumab in axSpA patients. They found that bimekizumab had sustained and consistent efficacy in patients with nr-axSpA and r-axSpA.
Patients were randomised 1:1 to bimekizumab and placebo in the parallel Phase 3 studies. After Week 16, the placebo group was switched to bimekizumab and both treatment arms were monitored up to Week 52.
Keywords:
